Global Cancer Cachexia Market Report and Forecast 2024-2032

Global Cancer Cachexia Market Outlook

The global cancer cachexia market size attained a value of USD 2.32 billion in 2023 driven by continuous clinical trials in oncology, expanding mindfulness among individuals and healthcare experts, presence of an enormous pool of undiscovered patients, quick urbanisation, and expanding government support for healthcare. The market is anticipated to grow at a CAGR of 4.7% during the forecast period of 2024-2032 to attain a value of USD 3.51 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Cancer Cachexia Market Likely to be Driven by Rising Number of Cachexia Cases and Advancements in Treatment Systems

The global market for cancer cachexia is expected to be driven by rising instances of cachexia and developments in modern treatment systems. North America, Europe and Japan are expected to be key markets. Cases of cachexia are growing and presently, the condition affects nearly 1 percent of all patients. Recent years have witnessed increased understanding of the multifarious nature of cachexia, in particular, the function of inflammatory mediators and anabolic and catabolic imbalances. While many treatment methodologies have not been able to clear phase III clinical trials despite initial promise, the ghrelin receptor agonist anamorelin has delivered initial results.

Cachexia is a serious outcome of a variety of chronic conditions, and associated with a poor quality of life. In last-stage chronic heart failure, the occurrence of cachexia ranges from 5–15 percent; in cases of advanced cancer, the incidence of cachexia lies between 50–80 percent. Many people with chronic renal disease, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis develop cachexia as they near the end of their lives. Cachectic syndrome is a key source of morbidity and mortality in cancer patients. Cancer cachexia has also been linked to decreased chemotherapeutic efficacy, increased adverse effects, and discontinuation of treatment. Progressive cachexia signals poor prognosis with a shorter survival time, and explains close to 20 percent of all cancer deaths. If there is weight loss of 10 percent or more within a period of 6 months, it may indicate presence of cachexia. There is a direct relation between survival of cancer patients and rate and amount of weight loss.

Cachectic syndrome is described to have three stages - precachexia, cachexia, and refractory cachexia. In the precachectic stage, indications such as such as weight loss (less than 5 percent), anorexia, and impaired glucose tolerance appear. Advancement to cachexia depends on several factors including systemic inflammation, type and stage of cancer, low food intake, and response to treatment. In refractory cachexia, active weight loss management is rendered almost impossible due to active catabolism or presence of cachectic factors. Patients experiencing acute muscle wasting are not likely to gain from treatments aimed at achieving   lean tissue and function. In this phase, therapy seeks to mitigate symptoms and reduce distress rather than prolong life.

Combination Therapies Involving Novel Medicinal Agents Show Promise; New Drugs Expected to Stimulate Market

At present, cancer cachexia is incurable. Current therapies for cachexia entail a multidisciplinary approach; combination therapy including diet adjustments and exercise (where possible) has been integrated with new medicinal agents such as Megestrol acetate, medroxyprogesterone, ghrelin, and omega-3-fatty acid, among others. These treatments have been reported to yield better survival rates and quality of life. Advancements in treatment systems and promise shown by under-trial drugs are expected to boost the market.

In 2021, Helsinn, a Swiss pharmaceutical group engaged in the production of high-quality cancer care and rare disease products, announced the first launch of Adlumiz^o (anamorelin) to treat cancer cachexia in malignant non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer in Japan, through Ono Pharmaceutical, its partner firm. Adlumiz^o (anamorelin), approved by the Japanese Health Authorities, has been shown to be effective in increasing body weight, muscle mass, and appetite in cancer cachexia patients.

AV-380 by AVEO is first-in-class, potent, humanized inhibitory IgG1 antibody targeting growth differentiation factor 15 (GDF15). Preclinical data suggest that inhibition of GDF15 leads to a switch from catabolism to anabolism, which indicates that GDF15 inhibition with AV-380 may reverse the effects of cachexia. As of 2023, AVEO Oncology completed enrolment in its phase I trial in Cachexia (In volunteers) in USA (Parenteral) (NCT04815551), and planned to commence a phase Ib trial in Cancer in mid-2022.

Global Cancer Cachexia Market Segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

By therapeutics, the market is divided into:

• Progestogens
• Corticosteroids
• Combination Therapy
• Others

By mechanism of action, the market is classified into:

• Appetite Stimulators
• Weight Loss Stabilizers

By distribution channel, the market is segmented into:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By region, the market is classified into:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Industry Players in the Global Cancer Cachexia Market

The report presents a detailed analysis of the following key players in the market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Merck & Co., Inc.
• Aphios Corporation
• Helsinn Healthcare SA
• AVEO Pharmaceuticals, Inc.
• Ono Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report